- Scapho 150mg/ml Injection belongs to the class of monoclonal antibodies. It is primarily indicated for the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy, active psoriatic arthritis (PsA) in patients two years and older
- adults with active ankylosing spondylitis (AS), adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Scapho 150mg/ml Injection consists of Secukinumab. It works by inhibiting the release of inflammatory cytokines and chemokines that contribute to autoimmune and inflammatory diseases.








